Cardiovascular-Kidney-Metabolic (CKM) Syndrome , as defined by the AHA, is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors (such as obesity, insulin resistance, dyslipidemia, and hypertension), chronic kidney disease (CKD), and the cardiovascular system, leading to multiorgan dysfunction and a high rate of adverse cardiovascular outcomes [145]
Under the Medicare Part D outpatient prescription drug benefit program, Part D plans are required to cover a minimum of two drugs in each therapeutic category and class, but from the outset, Medicare has been prohibited by law from covering medications when used specifically for weight loss
Women of childbearing age should use reliable contraception while on semaglutide and stop the medication at least two months before trying to conceive
These trials followed patients receiving GLP-1 agents for several years while closely monitoring adverse events
Animal LD50 studies in mice showed approximately 320 mg per kilogram of body weight, which translates to roughly 22,400 mg for a 154-pound human